Pramlintide
Amylin analogue
Pramlintide is an amylin analogue. Its labeled role was as an add-on to mealtime insulin for selected people with type 1 or type 2 diabetes who had not met their blood sugar goals despite optimized insulin treatment. MedlinePlus reports the injection was discontinued in the United States.
Evidence Level: Moderate Evidence
Some human data, strong animal studies, plausible mechanism
Regulatory Status: SymlinPen has FDA labeling for a defined diabetes use. MedlinePlus reports that the injection was discontinued in the United States.
How It Works
Potential Benefits
- The approved labeling describes blood sugar outcomes in selected people using mealtime insulin.
Risks & Considerations
- The boxed warning describes severe low blood sugar when used with insulin. The label requires close clinical supervision.
Sources and regulatory records
Related Peptides
Disclaimer: This information is for educational purposes only and is not medical advice. Many peptides discussed are not FDA-approved for human use. Always consult with a qualified healthcare provider before starting any treatment. Evidence levels and regulatory status can change, this content was last updated November 2026.
See a problem or outdated information? Tell us.